The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Aurobindo Pharma USA, Inc. has initiated a Drug Product Recall for the product Cinacalcet Tablets 30/60/90mg from USA market due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso-Cinacalcet above acceptable intake (AI) limit.

Cinacalcet Tablets are indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. To date, Aurobindo has not received any reports of adverse drug events that are confirmed with this recall. Patients who are prescribed Cinacalcet should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.

As per the product information leaflet, Cinacalcet tablets, 30 mg are light green, film-coated, oval shaped, biconvex tablets debossed with "80" on one side and "Y" on the other side. Cinacalcet tablets, 60 mg are light green, film-coated, oval shaped, biconvex tablets debossed with "81" on one side and "Y" on the other side. Cinacalcet tablets, 90 mg are light green, film-coated, oval shaped, biconvex tablets debossed with "82" on one side and "Y" on the other side.

Aurobindo USA began shipping impacted batches to customers nationwide from May 22, 2023 to March 14, 2024.

Batches manufactured at Aurobindo Pharma Unit VII

| NDC Number | Dosage Strength | Package Size | Lot Number | Expiration Date |
|--------------|------------------------|--------------|-------------|------------------------|
| 65862-831-30 | 30mg | | CFSA23001A | 03/2025 |
| | | | CFSA23002A | 03/2025 |
| | | 30's HDPE | C.FSA23003A | 03/2025 |
| | | | CFSA23004A | 07/2025 |
| | | Container | CFSA23005A | 10/2025 |
| 65862-832-30 | 60mg | | CFSB23001A | 03/2025 |
| | | | CFSB23002A | 07/2025 |
| | | | CFSB23003A | 10/2025 |

| | | CFSB23004A | 10/2025 |
|--------------|------|------------|---------|
| 65862-833-30 | 90mg | CFSC23001A | 03/2025 |
| | | CFSC23001B | 03/2025 |

Batches manufactured at APPCO Pharma LLC, USA

| NDC Number | Dosage Strength | ı Package Size | Lot Number | Expiration Date |
|--------------|-----------------|----------------------|------------|------------------------|
| 65862-831-05 | 30mg | 500's HDPE Container | P2300191 | 12/2024 |
| | | | P2300192 | |
| | | | P2300193 | |
| | | | P2300194 | |
| 65862-832-05 | 60mg | | P2300196 | |
| 65862-833-05 | 90mg | | P2300195 | |